Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
3,703 stopped studies mapped to Carcinoma and descendants · 91% state a reason
Over the 3,703 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00026468 | Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis | Phase 2 / Phase 3 | withdrawn | Jan 27, 2003 | University of Utah | Principle Investigator has left the University. | Investigator |
| NCT00673049 | Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer(NSCLC) | Phase 3 | terminated | May 7, 2008 | Pfizer | See termination reason in detailed description. | Other (stated, no rule matched) |
| NCT00942838 | Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the…(WAR) | Phase 1 | withdrawn | Jul 21, 2009 | University of Utah | PI decision due to under accrual. | Enrollment / accrual |
| NCT01006226 | 64CuATSM and Hypoxia in Stage IV Non-small Cell Lung Cancer With Carboplatin, Paclitaxel,… | N/A | withdrawn | Nov 2, 2009 | Washington University School of Medicine | Withdrawn due to funding issues | Funding |
| NCT00557830 | Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated… | Phase 2 | terminated | Nov 14, 2007 | Accelerated Community Oncology Research Network | The study was closed to enrollment when it became clear that enrollment was too slow to complete… | Enrollment / accrual |
| NCT00003486 | Antineoplaston Therapy in Treating Patients With Colon Cancer | Phase 2 | withdrawn | Jan 27, 2003 | Burzynski Research Institute | not stated | Not stated |
| NCT00003514 | Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic… | Phase 2 | withdrawn | Jan 27, 2003 | Burzynski Research Institute | not stated | Not stated |
| NCT00003517 | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer | Phase 2 | withdrawn | Jan 27, 2003 | Burzynski Research Institute | not stated | Not stated |
| NCT00040989 | BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer | Phase 2 | withdrawn | Jan 27, 2003 | Jonsson Comprehensive Cancer Center | not stated | Not stated |
| NCT00896467 | Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer… | — | terminated | May 11, 2009 | Centre Oscar Lambret | not stated | Not stated |
| NCT01073644 | Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent)… | — | terminated | Feb 23, 2010 | Pfizer | The study was prematurely discontinued due to poor recruitment on 18th April 2013. There were no… | Safety / toxicity |
| NCT00098527 | FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction… | Phase 2 | terminated | Dec 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00098618 | Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic… | Phase 2 | terminated | Dec 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00906360 | Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or… | Phase 1 | terminated | May 21, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01282333 | Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced… | Phase 1 | terminated | Jan 25, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01337154 | First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer | Phase 2 | terminated | Apr 18, 2011 | CytRx | Interim analysis showed that the primary endpoint would not be met. | Efficacy / futility |
| NCT00773383 | A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on… | Phase 2 | terminated | Oct 16, 2008 | Hoffmann-La Roche | not stated | Not stated |
| NCT01834183 | Tivozanib + Gemcitabine in Metastatic RCC | Phase 2 | withdrawn | Apr 17, 2013 | Dana-Farber Cancer Institute | Sponsor Aveo has withdrawn support for this trial. | Other (stated, no rule matched) |
| NCT01257035 | Predictive Value of 18F-FAZA in Rectum Cancer(FAZA) | — | terminated | Dec 9, 2010 | Vejle Hospital | The logistics of this trial (incl. supply of tracer) in connection with the patients' treatment… | Drug supply |
| NCT00087269 | Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing… | Phase 2 | terminated | Jul 12, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00084461 | Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | Phase 2 | terminated | Jun 11, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00615628 | Inheritance of Osteosarcoma & Paget's Disease Through Chromosome 18: | — | terminated | Feb 14, 2008 | State University of New York - Upstate Medical University | low enrollment low enrollment | Enrollment / accrual |
| NCT00697476 | Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive… | Phase 1 / Phase 2 | terminated | Jun 13, 2008 | Armando Santoro, MD | insufficient enrollment | Enrollment / accrual |
| NCT00758134 | Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients | Phase 2 | terminated | Sep 23, 2008 | Armando Santoro, MD | Insufficient accrual | Enrollment / accrual |
| NCT01859169 | Safety and Efficiency of Photodynamic Therapy for Blie Duct Carcinoma | — | suspended | May 21, 2013 | li xiong | Modifying the clinnicaltrials | Other (stated, no rule matched) |
| NCT01194427 | A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer | Phase 2 | terminated | Sep 3, 2010 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Difficulty meeting patient accrual goals | Enrollment / accrual |
| NCT01219907 | Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in… | Phase 1 | withdrawn | Oct 13, 2010 | University of Washington | not stated | Not stated |
| NCT01736878 | Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma(SUMMIT) | Phase 2 | withdrawn | Nov 29, 2012 | Eanm Research Ltd | Study was withdrawn due to unanticipated hassle in patient recruitment. | Enrollment / accrual |
| NCT00012246 | Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract | Phase 2 | terminated | Jan 27, 2003 | The University of Texas Medical Branch, Galveston | Administratively Terminated | Other (stated, no rule matched) |
| NCT01674374 | Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have… | Phase 2 | withdrawn | Aug 28, 2012 | Roswell Park Cancer Institute | not stated | Not stated |
| NCT00005812 | Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or… | Phase 2 | terminated | Jan 27, 2003 | Dartmouth-Hitchcock Medical Center | No objective response documented, protocol terminated after 12 patients. | Other (stated, no rule matched) |
| NCT00916669 | A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in… | Phase 2 | withdrawn | Jun 9, 2009 | Massachusetts General Hospital | sponsor withdrew funding prior to patient enrollment | Enrollment / accrual |
| NCT00004856 | Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic… | Phase 2 | terminated | Sep 30, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01781442 | A Post Marketing Surveillance As Required By Philippine Food And Drug Administration | — | withdrawn | Feb 1, 2013 | Pfizer | not stated | Not stated |
| NCT00491075 | Pemetrexed Plus Gemcitabine in Renal Cell Cancer | Phase 2 | terminated | Jun 25, 2007 | M.D. Anderson Cancer Center | Closed early for poor accrual. | Enrollment / accrual |
| NCT00268255 | Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II… | Phase 1 / Phase 2 | withdrawn | Dec 22, 2005 | Barbara Ann Karmanos Cancer Institute | Study never moved forward with accrual. | Enrollment / accrual |
| NCT01466504 | Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in… | — | terminated | Nov 8, 2011 | Dartmouth-Hitchcock Medical Center | Accrual did not meet expectations. Over nearly 2 years just 4 subjects were treated on study. The… | Enrollment / accrual |
| NCT00818090 | Paclitaxel and Cisplatin for Thymic Neoplasm | Phase 2 | terminated | Jan 7, 2009 | Korean Cancer Study Group | marginal statistical significance | Other (stated, no rule matched) |
| NCT00828594 | Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With… | Phase 1 | terminated | Jan 26, 2009 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT01329809 | Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma… | Phase 2 | terminated | Apr 6, 2011 | Jennerex Biotherapeutics | not stated | Not stated |
| NCT01616186 | Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) | Phase 2 | withdrawn | Jun 11, 2012 | Andrea Harzstark | not stated | Not stated |
| NCT00025051 | Celecoxib in Preventing Skin Cancer | Phase 2 | withdrawn | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00405561 | Study to Evaluate Progression Free Survival in Cancer Patients With Advanced Colorectal… | Phase 2 / Phase 3 | terminated | Nov 30, 2006 | Auron Healthcare GmbH | Lack of efficacy | Efficacy / futility |
| NCT00405873 | Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular… | Phase 2 | terminated | Nov 30, 2006 | Auron Healthcare GmbH | Lack of efficacy | Efficacy / futility |
| NCT00091195 | Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or… | Phase 2 | terminated | Sep 9, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT01088620 | Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line… | Phase 2 | suspended | Mar 17, 2010 | WiSP Wissenschaftlicher Service Pharma GmbH | the DSMB stopped the trial due to unacceptable side effects in the experimental arm which has not… | Other (stated, no rule matched) |
| NCT00937482 | Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases… | Phase 1 | terminated | Jul 13, 2009 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00429026 | Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell… | Phase 2 | terminated | Jan 31, 2007 | M.D. Anderson Cancer Center | Slow accrual, study terminated. | Enrollment / accrual |
| NCT00126607 | Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer | Phase 2 | terminated | Aug 4, 2005 | National Cancer Institute (NCI) | Poor accrual. | Enrollment / accrual |
| NCT00601120 | RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic… | N/A | withdrawn | Jan 25, 2008 | Beth Israel Deaconess Medical Center | This protocol was never officially opened and no patients were recruited. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Jul 24, 2013source: clinicaltrials